Fidelity is considering broadening eligibility for its Ethereum-based tokenized money market fund, currently limited to professional and institutional investors, and may introduce daily or intraday yield features. The firm has two existing products: the Fidelity Digital Interest Token (FDIT) and the Fidelity USD Digital Liquidity Fund (FILQ), both designed for large investors with high minimum investments. Expanding access could attract new participants and further integrate tokenized funds into the broader $15 billion tokenized Treasury and liquidity market. Investors should watch for official announcements on eligibility changes, minimum investment adjustments, and yield schedules.
Fidelity's Ethereum tokenized money market fund is the subject, with Pluang market data providing context. As of Oct 03, 2026 00:31 WIB, 25 of 50 major cryptocurrencies rose and 24 fell on Pluang. Notable gainers include BAT at Rp1.730 (+8.45%), AAVE at Rp3.263.620 (+8.21%), and EOS at Rp12.649 (+8.13%).
NetApp's stock price target was increased from $215 to $260 following its robust fiscal 2027 Q1 results, which included $2.03 billion in revenue and $2.58 non-GAAP earnings per share, both exceeding estimates. The company is advancing its AI infrastr...
NextEra Energy and partners are developing Project Star, a $22.3 billion natural gas-powered energy campus in Encinal, Texas, aimed at powering a large data center and supplying the grid. The campus will have 6.47 gigawatts of generation capacity, wi...
UBS has increased its price target for G-III Apparel Group to $27.00 from $26.00, reflecting confidence in the company's financial health and market position. Although the current share price slightly exceeds UBS's target, other analysts see potentia...
Enerflex secured a contract to build about 450 megawatts of natural gas-fired power units for a North American data center developer, with deliveries starting in 2027 and completing in 2028. The company’s 2026 capital spending includes $15 million fo...
Nektar Therapeutics has been downgraded from Strong Buy to Hold due to safety concerns related to its drug REZPEG, despite positive efficacy results from the Phase 2b REZOLVE-AA study. The study showed 63% durability off-treatment but revealed a high...
